Ms. Lu has extensive experience in all phases of patent litigation from pre-suit patent analysis through trial and appeal, including experience with federal bench and jury trials, summary judgment proceedings, preliminary injunction proceedings, and Federal Circuit appeals.
Ms. Lu also has experience working on arbitrations involving contract disputes in the life sciences space, and inter partes review proceedings before the U.S. Patent Trial and Appeal Board.
Representative matters include:
- GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc., No. 14-878-LPS (D. Del.) – Represented Teva in patent litigation, including jury trial, concerning Teva’s generic version of Coreg® (carvedilol) tablets.
- Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., No. 17-7111 (D. N.J.) – Representing Dr. Reddy’s in patent infringement litigation, including a hearing on motion for a preliminary injunction, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films.
- Reckitt Benckiser Pharmaceuticals Inc. v. Dr. Reddy’s Laboratories, S.A., No. 14-1451-RGA (D. Del.) – Represented Dr. Reddy’s in patent infringement litigation, including bench trial, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films. After trial, the court found that Dr. Reddy’s proposed generic product did not infringe any of the asserted patents.
- Genentech, Inc. v. Celltrion, Inc., No. 18-cv-0574 (D. N.J.) – Represented Celltrion and Teva in patent infringement litigation under the BPCIA, including preparations for hearing on motion for a preliminary injunction, concerning Celltrion’s and Teva’s proposed biosimilar rituximab product.
- Sophos, Inc. v. RPost Holdings, Inc., No. 13-12856-DJC (D. Mass.) – Represented Sophos in declaratory judgment action regarding Sophos’s network security and email security products. The court granted Sophos’s motion for summary judgment of invalidity on two independent grounds.
- Genzyme Corp. v. Dr. Reddy’s Labs., Ltd., No. 13-1506-GMS (D. Del.) – Represented Teva Pharmaceuticals USA, Inc. in patent infringement litigation, including trial, regarding Teva’s application to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
Ms. Lu is also committed to pro bono work, in which she has focused on matters representing unaccompanied minors seeking asylum and Special Immigrant Juvenile status in immigration and related state court proceedings. Ms. Lu was also an active member of a team that successfully challenged, on First Amendment grounds, city ordinances banning charitable solicitation in public places, and a team that successfully won an immigration case before the Supreme Court concerning the correct interpretation of the stop-time rule for cancellation of removal.